PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ORAL DOSES OF MK-0591, A 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR

被引:22
作者
DEPRE, M
FRIEDMAN, B
VANHECKEN, A
DELEPELEIRE, I
TANAKA, W
DALLOB, A
SHINGO, S
PORRAS, A
LIN, C
DESCHEPPER, PJ
机构
[1] KATHOLIEKE UNIV LEUVEN,SCH MED,DEPT PHARMACOL,B-3000 LOUVAIN,BELGIUM
[2] KATHOLIEKE UNIV LEUVEN,SCH PHARM,DEPT PHARMACOL,B-3001 LOUVAIN,BELGIUM
[3] MERCK SHARP & DOHME LTD,RES LABS,RAHWAY,NJ
关键词
D O I
10.1038/clpt.1994.96
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacodynamics, kinetics, and tolerability of a new orally active 5-lipoxygenase inhibitor were evaluated in healthy male volunteers. MK-0591, 50, 125, and 250 mg every morning and 250 mg every 12 hours, was administered for 10 days. Leukotriene B-4 biosynthesis ex vivo in ionophore (A23187)stimulated whole blood and leukotriene E(4) levels in urine were determined. Leukotriene B, production was inhibited up to 90% of baseline for 12 hours after administration at the highest dose. The degree of leukotriene B-4 inhibition ex vivo in whole blood significantly correlated with plasma MK-0591 concentrations (0 to 1500 ng/ml; r = 0.73). Urinary leukotriene E(4) was inhibited by > 80% at 24 hours after administration for all dose levels. Pharmacokinetics of MR-0591 were linear, with a half-life of approximately 6 hours. Very little accumulation was seen after multiple dosing. MR-0591 had no effect on testosterone levels, and good tolerability was shown at all dose levels of MK-0591 administered for up to 10 days.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 37 条
[1]   SIMPLE METHOD FOR ASSAY OF 8 STEROIDS IN SMALL VOLUMES OF PLASMA [J].
ANDERSON, DC ;
HOPPER, BR ;
LASLEY, BL ;
YEN, SSC .
STEROIDS, 1976, 28 (02) :179-196
[2]  
BEL EH, 1993, AM REV RESPIR DIS, V147, P839
[3]   LEUKOTRIENE-B4 - A MEDIATOR OF VASCULAR-PERMEABILITY [J].
BRAY, MA ;
CUNNINGHAM, FM ;
FORDHUTCHINSON, AW ;
SMITH, MJH .
BRITISH JOURNAL OF PHARMACOLOGY, 1981, 72 (03) :483-486
[4]   PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR [J].
BRIDEAU, C ;
CHAN, C ;
CHARLESON, S ;
DENIS, D ;
EVANS, JF ;
FORDHUTCHINSON, AW ;
FORTIN, R ;
GILLARD, JW ;
GUAY, J ;
GUEVREMONT, D ;
HUTCHINSON, JH ;
JONES, TR ;
LEGER, S ;
MANCINI, JA ;
MCFARLANE, CS ;
PICKETT, C ;
PIECHUTA, H ;
PRASIT, P ;
RIENDEAU, D ;
ROUZER, CA ;
TAGARI, P ;
VICKERS, PJ ;
YOUNG, RN ;
ABRAHAM, WM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) :799-807
[5]   RADIOIMMUNOASSAY OF LTB4 AND 6-TRANS LTB4 - ANALYTICAL AND PHARMACOLOGICAL CHARACTERIZATION OF IMMUNOREACTIVE LTB4 IN IONOPHORE STIMULATED HUMAN-BLOOD [J].
CAREY, F ;
FORDER, RA .
PROSTAGLANDINS LEUKOTRIENES AND MEDICINE, 1986, 22 (01) :57-70
[6]   STIMULATION OF HUMAN MYELOPOIESIS BY LEUKOTRIENE-B4 [J].
CLAESSON, HE ;
DAHLBERG, N ;
GAHRTON, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 131 (02) :579-585
[7]   LEUKOTRIENES ARE POTENT CONSTRICTORS OF HUMAN BRONCHI [J].
DAHLEN, SE ;
HEDQVIST, P ;
HAMMARSTROM, S ;
SAMUELSSON, B .
NATURE, 1980, 288 (5790) :484-486
[8]  
DENZLINGER C, 1990, BLOOD, V76, P1765
[9]   BIOCHEMICAL-ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF MK-886, A LEUKOTRIENE BIOSYNTHESIS INHIBITOR, IN HUMANS [J].
DEPRE, M ;
FRIEDMAN, B ;
TANAKA, W ;
VANHECKEN, A ;
BUNTINX, A ;
DESCHEPPER, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (05) :602-607
[10]   PLASMA DRUG PROFILES AND TOLERABILITY OF MK-571 (L-660,711), A LEUKOTRIENE D4 RECEPTOR ANTAGONIST, IN MAN [J].
DEPRE, M ;
MARGOLSKEE, DJ ;
HSIEH, JYK ;
VANHECKEN, A ;
BUNTINX, A ;
DELEPELEIRE, I ;
ROGERS, JD ;
DESCHEPPER, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) :427-430